For: |
Caro SD, Fini L, Daoud Y, Grizzi F, Gasbarrini A, Lorenzo AD, Renzo LD, McCartney S, Bloom S. Levofloxacin/amoxicillin-based schemes |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v18/i40/5669.htm |
Number | Citing Articles |
1 |
Sinéad Marian Smith. An Update on the Treatment of Helicobacter Pylori Infection. EMJ Gastroenterology 2015; : 101 doi: 10.33590/emjgastroenterol/10310813
|
2 |
Yee Hui Yeo, Chia‐Chen Hsu, Chiao‐Chin Lee, Hsiu J Ho, Jaw‐Town Lin, Ming‐Shiang Wu, Jyh‐Ming Liou, Chun‐Ying Wu. Systematic review and network meta‐analysis: Comparative effectiveness of therapies for second‐line Helicobacter pylori eradication. Journal of Gastroenterology and Hepatology 2019; 34(1): 59 doi: 10.1111/jgh.14462
|
3 |
Hale Gokcan, Erkin Oztas, Ibrahim Koral Onal. Different bismuth-based therapies for eradicating Helicobacter pylori: Randomized clinical trial of efficacy and safety. Clinics and Research in Hepatology and Gastroenterology 2016; 40(1): 124 doi: 10.1016/j.clinre.2015.06.014
|
4 |
Joo Hyun Lim, Sang Gyun Kim, Ji Hyun Song, Jae Jin Hwang, Dong Ho Lee, Jae Pil Han, Su Jin Hong, Ji Hyun Kim, Seong Woo Jeon, Gwang Ha Kim, Ki-Nam Shim, Woon Geon Shin, Tae Ho Kim, Sun Moon Kim, Il-Kwon Chung, Hyun-Soo Kim, Heung Up Kim, Joongyub Lee, Jae Gyu Kim. Efficacy of Levofloxacin-Based Third-Line Therapy for the Eradication of Helicobacter pylori in Peptic Ulcer Disease. Gut and Liver 2017; 11(2): 226 doi: 10.5009/gnl16099
|
5 |
Todor Asenov Angelov, Mila Dimitrova Kovacheva-Slavova, Hristo Ilianov Iliev, Hristo Yankov Valkov, Borislav Georgiev Vladimirov. Gastritis - New Approaches and Treatments. 2019; doi: 10.5772/intechopen.86963
|
6 |
Te-Fu Lin, Ping-I Hsu. Second-line rescue treatment of <i>Helicobacter pylori</i> infection: Where are we now?. World Journal of Gastroenterology 2018; 24(40): 4548-4553 doi: 10.3748/wjg.v24.i40.4548
|
7 |
Sung Bum Kim, Si Hyung Lee, Kyeong Ok Kim, Byung Ik Jang, Tae Nyeun Kim. Ten-day Sequential TherapyversusBismuth Based Quadruple Therapy as Second Line Treatment forHelicobacter pyloriInfection. The Korean Journal of Gastroenterology 2015; 66(5): 261 doi: 10.4166/kjg.2015.66.5.261
|
8 |
Francis Mégraud.
Current recommendations for
Helicobacter pylori
therapies in a world of evolving resistance
. Gut Microbes 2013; 4(6): 541 doi: 10.4161/gmic.25930
|
9 |
Javier P. Gisbert. Optimization Strategies Aimed to Increase the Efficacy of Helicobacter pylori Eradication Therapies with Quinolones. Molecules 2020; 25(21): 5084 doi: 10.3390/molecules25215084
|
10 |
Vasilios Papastergiou, Sotirios D Georgopoulos, Stylianos Karatapanis. Treatment of <italic>Helicobacter pylori</italic> infection: Meeting the challenge of antimicrobial resistance. World Journal of Gastroenterology 2014; 20(29): 9898-9911 doi: 10.3748/wjg.v20.i29.9898
|
11 |
Samuel Costa, João-Bruno Soares, Raquel Gonçalves. Efficacy and tolerability of culture-guided treatment for Helicobacter pylori infection. European Journal of Gastroenterology & Hepatology 2017; 29(11): 1258 doi: 10.1097/MEG.0000000000000960
|
12 |
Priscila Baptistella Yazbek, Ariane Biolcati Trindade, Chung Man Chin, Jean Leandro dos Santos. Challenges to the Treatment and New Perspectives for the Eradication of Helicobacter pylori. Digestive Diseases and Sciences 2015; 60(10): 2901 doi: 10.1007/s10620-015-3712-y
|
13 |
Jyh‐Ming Liou, Ming‐Shiang Wu, Jaw‐Town Lin. Treatment of Helicobacter pylori infection: Where are we now?. Journal of Gastroenterology and Hepatology 2016; 31(12): 1918 doi: 10.1111/jgh.13418
|
14 |
Javier P. Gisbert, Javier Alcedo, Javier Amador, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Luis Fernández-Salazar, Emili Gené, Ángel Lanas, Alfredo Lucendo, Javier Molina-Infante, Olga P. Nyssen, A. Pérez-Aisa, Ignasi Puig. V Spanish Consensus Conference on Helicobacter pylori infection treatment. Gastroenterología y Hepatología (English Edition) 2022; 45(5): 392 doi: 10.1016/j.gastre.2021.07.001
|
15 |
Bojan Tepes, Natasa Brglez Jurecic, Katja Tepes, Marta Espada Sanchez, Olga Perez Nyssen, Colm O’Morain, Francis Mégraud, Javier Gisbert. <b><i>Helicobacter pylori</i></b> Eradication Rates in Slovenia in the Period from 2017 to 2019: Data from the European Registry on <b><i>H. pylori</i></b> Management. Digestive Diseases 2021; 39(4): 318 doi: 10.1159/000512506
|
16 |
Bor‐Shyang Sheu, Ming‐Shiang Wu, Cheng‐Tang Chiu, Jing‐Chuan Lo, Deng‐Chyang Wu, Jyh‐Ming Liou, Chun‐Ying Wu, Hsiu‐Chi Cheng, Yi‐Chia Lee, Ping‐I Hsu, Chun‐Chao Chang, Wei‐Lun Chang, Jaw‐Town Lin. Consensus on the clinical management, screening‐to‐treat, and surveillance of Helicobacter pylori infection to improve gastric cancer control on a nationwide scale. Helicobacter 2017; 22(3) doi: 10.1111/hel.12368
|
17 |
Jinfeng Dai, Jing Zhao, Liqi Mao, Yue Hu, Bin Lv. Study on the value of antibiotic‑resistant gene detection in Helicobacter pylori in China. Experimental and Therapeutic Medicine 2022; 23(3) doi: 10.3892/etm.2022.11153
|
18 |
Faezeh Kiani, Sara Khademolhosseini, Jasem Mohammadi, Arian Tavasol, Ramtin Hajibeygi, Mobina Fathi, Majid Dousti. Novel Information Regarding the Treatment of Helicobacter pylori Infection:
A Systematic Review and Meta-analysis of Randomized Clinical Trials. Current Reviews in Clinical and Experimental Pharmacology 2024; 19(2): 184 doi: 10.2174/2772432818666230120111237
|
19 |
Richard J.M. Ingram, Krish Ragunath, John C. Atherton. Yamada' s Textbook of Gastroenterology. 2015; : 1032 doi: 10.1002/9781118512074.ch56
|
20 |
Anthony O'Connor, Javier Molina‐Infante, Javier P. Gisbert, Colm O'Morain. Treatment of Helicobacter pylori Infection 2013. Helicobacter 2013; 18(s1): 58 doi: 10.1111/hel.12075
|
21 |
Eman T. Azab, Abrar K. Thabit, Sean McKee, Aymen Al-Qiraiqiri. Levofloxacin versus clarithromycin for Helicobacter pylori eradication: are 14 day regimens better than 10 day regimens?. Gut Pathogens 2022; 14(1) doi: 10.1186/s13099-022-00502-3
|
22 |
Oddmund Nestegard, Kay-Martin Johnsen, Sveinung W. Sørbye, Fred-Arne Halvorsen, Tor Tønnessen, Eyvind J. Paulssen, Kjetil K. Melby, Rasmus Goll, Jon Florholmen, Iddya Karunasagar. Clinical characterization of Helicobacter pylori infected patients 15 years after unsuccessful eradication. PLOS ONE 2020; 15(9): e0238944 doi: 10.1371/journal.pone.0238944
|
23 |
Young Woon Chang, Ga Young Shin, Jung-Wook Kim, Jin-Chang Moon, Eun Jee Chang, Chi Hyuk Oh, Jae-Young Jang. Cost-Effectiveness of Empirical Bismuth-Based Quadruple Therapy and Tailored Therapy After Clarithromycin Resistance Tests for Helicobacter pylori Eradication. Digestive Diseases and Sciences 2022; 67(4): 1222 doi: 10.1007/s10620-021-06938-y
|
24 |
Recep ALANLI, Murat Bulent KUCUKAY, Muhammet Fatih AYDIN, Bilal ERGÜL, Fahri YAKARYILMAZ. EFFICACY AND SAFETY OF GEMIFLOXACIN CONTAINING TREATMENT REGIMEN IN FIRST-LINE TREATMENT OF HELICOBACTER PYLORI. Arquivos de Gastroenterologia 2023; 60(3): 350 doi: 10.1590/s0004-2803.230302-23-51
|
25 |
Su Yeon Rhie, Jae Yong Park, Tae-Seop Shin, Jeong Wook Kim, Beom Jin Kim, Jae Gyu Kim. Discovery of a Novel Mutation in DNA Gyrase and Changes in the Fluoroquinolone Resistance of Helicobacter pylori over a 14-Year Period: A Single Center Study in Korea. Antibiotics 2020; 9(6): 287 doi: 10.3390/antibiotics9060287
|
26 |
P Malfertheiner, F Megraud, C A O'Morain, J P Gisbert, E J Kuipers, A T Axon, F Bazzoli, A Gasbarrini, J Atherton, D Y Graham, R Hunt, P Moayyedi, T Rokkas, M Rugge, M Selgrad, S Suerbaum, K Sugano, E M El-Omar. Management ofHelicobacter pyloriinfection—the Maastricht V/Florence Consensus Report. Gut 2017; 66(1): 6 doi: 10.1136/gutjnl-2016-312288
|
27 |
Carlo A. Fallone, Naoki Chiba, Sander Veldhuyzen van Zanten, Lori Fischbach, Javier P. Gisbert, Richard H. Hunt, Nicola L. Jones, Craig Render, Grigorios I. Leontiadis, Paul Moayyedi, John K. Marshall. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults. Gastroenterology 2016; 151(1): 51 doi: 10.1053/j.gastro.2016.04.006
|
28 |
Antonio Tarasconi, Federico Coccolini, Walter L. Biffl, Matteo Tomasoni, Luca Ansaloni, Edoardo Picetti, Sarah Molfino, Vishal Shelat, Stefania Cimbanassi, Dieter G. Weber, Fikri M. Abu-Zidan, Fabio C. Campanile, Salomone Di Saverio, Gian Luca Baiocchi, Claudio Casella, Michael D. Kelly, Andrew W. Kirkpatrick, Ari Leppaniemi, Ernest E. Moore, Andrew Peitzman, Gustavo Pereira Fraga, Marco Ceresoli, Ronald V. Maier, Imtaz Wani, Vittoria Pattonieri, Gennaro Perrone, George Velmahos, Michael Sugrue, Massimo Sartelli, Yoram Kluger, Fausto Catena. Perforated and bleeding peptic ulcer: WSES guidelines. World Journal of Emergency Surgery 2020; 15(1) doi: 10.1186/s13017-019-0283-9
|
29 |
Luís Eduardo S Fontes, Ana Luiza C Martimbianco, Christieny Chaipp Mochdece, Rachel Riera. Proton pump inhibitor- and fluoroquinolone-based triple therapies forHelicobacter pylorieradication. Cochrane Database of Systematic Reviews 2017; doi: 10.1002/14651858.CD012588
|
30 |
Javier P. Gisbert, Javier Alcedo, Javier Amador, Luis Bujanda, Xavier Calvet, Manuel Castro-Fernández, Luis Fernández-Salazar, Emili Gené, Ángel Lanas, Alfredo J. Lucendo, Javier Molina-Infante, Olga P. Nyssen, A. Pérez-Aisa, Ignasi Puig. V Conferencia Española de Consenso sobre el tratamiento de la infección por Helicobacter pylori. Gastroenterología y Hepatología 2022; 45(5): 392 doi: 10.1016/j.gastrohep.2021.07.011
|
31 |
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Sheila López-Góngora, Xavier Calvet. Prevalencia de las resistencias de Helicobacter pylori tras el fracaso de una primera línea de tratamiento. Revisión sistemática. Gastroenterología y Hepatología 2018; 41(10): 654 doi: 10.1016/j.gastrohep.2018.06.014
|
32 |
Igor D. Zlotnikov, Natalya G. Belogurova, Irina V. Poddubnaya, Elena V. Kudryashova. Mucosal Adhesive Chitosan Nanogel Formulations of Antibiotics and Adjuvants (Terpenoids, Flavonoids, etc.) and Their Potential for the Treatment of Infectious Diseases of the Gastrointestinal Tract. Pharmaceutics 2023; 15(9): 2353 doi: 10.3390/pharmaceutics15092353
|
33 |
Masoud Keikha, Parvin Askari, Kiarash Ghazvini, Mohsen Karbalaei. Levofloxacin-based therapy as an efficient alternative for eradicating Helicobacter pylori infection in Iran: a systematic review and meta-analysis. Journal of Global Antimicrobial Resistance 2022; 29: 420 doi: 10.1016/j.jgar.2021.10.019
|
34 |
Antonio Rollan, Juan Pablo Arab, M Constanza Camargo, Roberto Candia, Paul Harris, Catterina Ferreccio, Charles S Rabkin, Juan Cristóbal Gana, Pablo Cortés, Rolando Herrero, Luisa Durán, Apolinaria García, Claudio Toledo, Alberto Espino, Nicole Lustig, Alberto Sarfatis, Catalina Figueroa, Javier Torres, Arnoldo Riquelme. Management of <italic>Helicobacter pylori</italic> infection in Latin America: A Delphi technique-based consensus. World Journal of Gastroenterology 2014; 20(31): 10969-10983 doi: 10.3748/wjg.v20.i31.10969
|
35 |
Rocco Maurizio Zagari, Marco Romano, Veronica Ojetti, Reinhold Stockbrugger, Sergio Gullini, Bruno Annibale, Fabio Farinati, Enzo Ierardi, Giovanni Maconi, Massimo Rugge, Carlo Calabrese, Francesco Di Mario, Francesco Luzza, Stefano Pretolani, Antonella Savio, Giovanni Gasbarrini, Michele Caselli. Guidelines for the management of Helicobacter pylori infection in Italy: The III Working Group Consensus Report 2015. Digestive and Liver Disease 2015; 47(11): 903 doi: 10.1016/j.dld.2015.06.010
|
36 |
Jason Ferreira, Steven F. Moss. Current Paradigm and Future Directions for Treatment of Helicobacter pylori Infection. Current Treatment Options in Gastroenterology 2014; 12(4): 373 doi: 10.1007/s11938-014-0027-6
|
37 |
Neus Muñoz, Jordi Sánchez-Delgado, Mireia Baylina, Sheila López-Góngora, Xavier Calvet. Prevalence of Helicobacter pylori resistance after failure of first-line therapy. A systematic review. Gastroenterología y Hepatología (English Edition) 2018; 41(10): 654 doi: 10.1016/j.gastre.2018.11.021
|
38 |
Keval A. Patel, Colin W. Howden. Update on the Diagnosis and Management of Helicobacter pylori Infection in Adults. Journal of Clinical Gastroenterology 2015; 49(6): 461 doi: 10.1097/MCG.0000000000000318
|
39 |
Yiqiao Xin, Jan Manson, Lindsay Govan, Robin Harbour, Jenny Bennison, Eleanor Watson, Olivia Wu. Pharmacological regimens for eradication of Helicobacter pylori: an overview of systematic reviews and network meta-analysis. BMC Gastroenterology 2016; 16(1) doi: 10.1186/s12876-016-0491-7
|
40 |
Giuseppe Losurdo, Fulvio Salvatore D’Abramo, Mariapaola Piazzolla, Raffaella Rima, Antonio Continisio, Maria Pricci, Enzo Ierardi, Alfredo Di Leo. Second-line Therapy for Helicobacter Pylori Eradication: State of the Art. Mini-Reviews in Medicinal Chemistry 2022; 22(19): 2430 doi: 10.2174/1389557522666220325153832
|
41 |
Chih-An Shih, Chang-Bih Shie, Wei-Chen Tai, Seng-Kee Chuah, Hsi-Chang Lee, Ping-I Hsu. Update on the second-line treatment of Helicobacter pylori infection: a narrative review. Therapeutic Advances in Gastroenterology 2023; 16 doi: 10.1177/17562848231192750
|
42 |
Sarah Courtois, Lucie Bénéjat, Julien Izotte, Francis Mégraud, Christine Varon, Philippe Lehours, Emilie Bessède.
Metformin can Inhibit
Helicobacter Pylori
Growth
. Future Microbiology 2018; 13(14): 1575 doi: 10.2217/fmb-2018-0184
|
43 |
Ping-I Hsu, Feng-Woei Tsai, Sung-Shuo Kao, Wen-Hung Hsu, Jin-Shiung Cheng, Nan-Jing Peng, Kuo-Wang Tsai, Huang-Ming Hu, Yao-Kuang Wang, Seng-Kee Chuah, Angela Chen, Deng-Chyang Wu. Ten-Day Quadruple Therapy Comprising Proton Pump Inhibitor, Bismuth, Tetracycline, and Levofloxacin is More Effective than Standard Levofloxacin Triple Therapy in the Second-Line Treatment of Helicobacter pylori Infection: A Randomized Controlled Trial. American Journal of Gastroenterology 2017; 112(9): 1374 doi: 10.1038/ajg.2017.195
|
44 |
Neus Muñoz, Jordi Sánchez‐Delgado, Mireia Baylina, Ignasi Puig, Sheila López‐Góngora, David Suarez, Xavier Calvet. Systematic review, meta‐analysis, and meta‐regression: Successful second‐line treatment forHelicobacter pylori. Helicobacter 2018; 23(3) doi: 10.1111/hel.12488
|
45 |
Van Huy Tran, Thi Mai Ngan Nguyen, Phan Tuong Quynh Le, Thi Huyen Thuong Nguyen, Thi Chau Loan Nguyen, Thi Minh Thi Ha. Current status of Helicobacter pylori resistance to clarithromycin and levofloxacin in Vietnam: Results from molecular analysis of gastric biopsy specimens. Journal of Global Antimicrobial Resistance 2024; 36: 76 doi: 10.1016/j.jgar.2023.12.026
|
46 |
Ping‐I Hsu, Feng‐Woei Tsay, John Y. Kao, Nan‐Jing Peng, Yan‐Hua Chen, Sheng‐Yeh Tang, Chao‐Hung Kuo, Sung‐Shuo Kao, Huay‐Min Wang, I‐Ting Wu, Chang‐Bih Shie, Seng‐Kee Chuah, Deng‐Chyang Wu. Tetracycline‐levofloxacin versus amoxicillin‐levofloxacin quadruple therapies in the second‐line treatment of Helicobacter pylori infection. Helicobacter 2021; 26(5) doi: 10.1111/hel.12840
|
47 |
Fernando Marcuz Silva, Elaine Cristina Silveira de Queiroz, Tomás Navarro-Rodriguez, Ricardo Correa Barbuti, Rejane Mattar, Kiyoshi Iriya, Jin Hwa Lee, Jaime Natan Eisig. Efficacy of levofloxacin, amoxicillin and a proton pump inhibitor in the eradication of Helicobacter pylori in Brazilian patients with peptic ulcers. Clinics 2015; 70(5): 318 doi: 10.6061/clinics/2015(05)02
|
48 |
I. N. Kupriyanova, V. A. Vedensky, E. Ya. Valieva, M. A. Sinitsina. Damage to the musculoskeletal system during eradication therapy of <i>Helicobacter pylori</i> with levofloxacin. Experimental and Clinical Gastroenterology 2021; (9): 114 doi: 10.31146/1682-8658-ecg-193-9-114-118
|